Research programme: anti-angiogenic ocular gene therapies - Advanced Vision Therapies

Drug Profile

Research programme: anti-angiogenic ocular gene therapies - Advanced Vision Therapies

Alternative Names: AVT-1; AVT-2

Latest Information Update: 04 Mar 2008

Price : $50

At a glance

  • Originator Advanced Vision Therapies
  • Class Gene therapies
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Age-related macular degeneration; Diabetic retinopathy; Retinitis pigmentosa

Most Recent Events

  • 13 Sep 2006 This programme is still in active development
  • 17 Aug 2004 Preclinical trials in Diabetic retinopathy in USA (unspecified route)
  • 17 Aug 2004 Preclinical trials in Age-related macular degeneration in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top